SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare trades higher on the bourses

18 Nov 2019 Evaluate

Cadila Healthcare is currently trading at Rs. 241.40, up by 7.05 points or 3.01% from its previous closing of Rs. 234.35 on the BSE.

The scrip opened at Rs. 236.65 and has touched a high and low of Rs. 242.40 and Rs. 236.65 respectively. So far 44522 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 370.00 on 03-Dec-2018 and a 52 week low of Rs. 206.45 on 22-Aug-2019.

Last one week high and low of the scrip stood at Rs. 242.40 and Rs. 219.00 respectively. The current market cap of the company is Rs. 24508.40 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.13% and 8.00% respectively.

Zydus Cadila has declared the second Phase III DREAM-D trials of Desidustat, an Investigational New Drug (IND) targeted at treating anemia in dialysis dependent CKD patients.

Desidustat is a novel, oral, HIF-PH inhibitor being developed for treating anemia in CKD patients. This Phase III DREAM-D study will be a multicenter (50- 60 sites in India), randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Epoetin for the treatment of anemia in patients with CKD who are on dialysis.

Cadila Healthcare is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

1121.65 20.15 (1.83%)
29-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.60
Dr. Reddys Labs. 1376.30
Cipla 1453.50
Zydus Lifesciences 1121.65
Lupin 2407.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: